VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for its lead BiTAC ® T-cell engager ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results